See more : Bombardier Inc. (BBD-B.TO) Income Statement Analysis – Financial Results
Complete financial analysis of SeaStar Medical Holding Corporation (ICU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SeaStar Medical Holding Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- APM Human Services International Limited (APM.AX) Income Statement Analysis – Financial Results
- PT Sunindo Pratama Tbk (SUNI.JK) Income Statement Analysis – Financial Results
- Dialog Semiconductor Plc (DLG.DE) Income Statement Analysis – Financial Results
- Hunter Maritime Acquisition Corp. (HUNTF) Income Statement Analysis – Financial Results
- Bilfinger SE (BFLBF) Income Statement Analysis – Financial Results
SeaStar Medical Holding Corporation (ICU)
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.97M | 2.82M | 2.77M | 4.03M |
| General & Administrative | 8.01M | 6.60M | 1.68M | 2.43M |
| Selling & Marketing | 32.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 8.04M | 6.60M | 1.68M | 2.43M |
| Other Expenses | 200.00K | 0.00 | 91.00K | 84.00K |
| Operating Expenses | 14.21M | 11.61M | 4.45M | 6.45M |
| Cost & Expenses | 14.21M | 11.61M | 4.45M | 6.45M |
| Interest Income | 0.00 | 630.00 | 212.00 | 3.31K |
| Interest Expense | 1.08M | 630.00K | 212.00K | 3.31M |
| Depreciation & Amortization | 14.01M | 11.61M | 4.45M | 6.45M |
| EBITDA | -11.14M | -11.61M | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.21M | -11.61M | -4.45M | -6.45M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.02M | -11.40M | -148.00K | 3.19M |
| Income Before Tax | -26.23M | -23.01M | -4.60M | -3.27M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.00K | -1.00K | 9.00K |
| Net Income | -26.23M | -23.01M | -4.60M | -3.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -30.29 | -70.16 | -15.90 | -27.15 |
| EPS Diluted | -30.26 | -70.07 | -15.87 | -27.15 |
| Weighted Avg Shares Out | 866.00K | 328.00K | 289.00K | 120.67K |
| Weighted Avg Shares Out (Dil) | 866.81K | 328.45K | 289.55K | 120.67K |
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update
Data illustrate the potential of QUELIMMUNE ™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024
Data illustrate the potential of QUELIMMUNE ™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury
SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers
DENVER, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that it has assumed all responsibility for direct sales,...
SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis
The pace of patient enrollment has significantly accelerated following a summertime slowdown DENVER, Oct. 18, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on...
SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week
DENVER, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the presentation of new analyses of clinical data further...
SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit
DENVER, Oct. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will participate in a fireside chat at...
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities
DENVER , Oct. 08, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the activation of Brooke Army Medical Center (BAMC)...
ICU Medical's Stock Rises Despite Bivona Tracheostomy Tube Recall
ICUI's Smiths Medical recalls Bivona tracheostomy tubes over a defect that may lead to serious health risks, including airway loss and death.
SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial
DENVER, Sept. 25, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the enrollment of four additional subjects in a 10-day...
The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against SeaStar Medical Holding Corporation
LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation ("SeaStar" or "the Company") (NASDAQ:ICU) for violations of...
Source: https://incomestatements.info
Category: Stock Reports